文献速递骨质疏松与钙磷/甲状旁腺

治疗性血浆置换对钙、磷、甲状旁腺激素及成纤维细胞生长因子-23的影响

Therapeutic Plasma Exchange and Changes in Calcium, Phosphate, Parathyroid Hormone, and Fibroblast Growth Factor-23.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本研究在42例接受治疗性血浆置换(TPE)的患者中,于置换前、后及随访时检测总钙、磷、甲状旁腺激素(PTH)和成纤维细胞生长因子-23(FGF-23)水平。TPE导致钙、磷、FGF-23急性下降,而PTH升高;随访时多数指标恢复基线,但近25%患者持续无症状性低钙血症,且静脉钙剂及内源性PTH升高未能完全纠正。结论强调需优化TPE患者的矿物质代谢监测与护理方案。

要点

  • TPE后钙、磷、FGF-23急性下降,PTH代偿性升高。
  • 近25%患者出现持续无症状性低钙血症。
  • 静脉钙剂及PTH升高不能完全纠正钙缺乏。

核心结论

  • TPE引起钙、磷、FGF-23急性降低及PTH升高,部分患者持续低钙血症。
  • 需改进TPE患者矿物质代谢的监测与护理方案。

研究设计与样本

  • 前瞻性观察性研究,纳入42例接受TPE的患者,平均年龄55±16岁,女性28例(67%),白人32例(76%)。
  • 在TPE前、后及随访时测量血浆及废液中总钙、磷、PTH和FGF-23水平,采用配对t检验比较百分比变化。

主要发现

  • TPE后钙下降9%(95%CI -11%至-8%),磷下降14%(-18%至-11%),FGF-23下降12%(-18%至-6%)。
  • PTH从基线至TPE后升高91%(63%-119%)。
  • 随访(中位4天,IQR 3-7天)时多数指标恢复基线,但近25%患者持续无症状性低钙血症。

临床怎么用

  • TPE患者应密切监测钙、磷、PTH及FGF-23,尤其长期治疗者。
  • 对持续低钙血症需考虑更积极的纠正措施,静脉钙剂可能不足。

局限性

  • 样本量较小(N=42),随访时间短(中位4天)。
  • 未明确持续低钙血症的具体机制及长期影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Therapeutic plasma exchange (TPE) removes plasma proteins and other unwanted substances, causing nonspecific alterations of plasma components. A previous study showed an approximately 70% reduction in vitamin D metabolites following a single TPE treatment, prompting further investigation into TPE's effects on vitamin D regulators and metabolites: calcium, phosphate, parathyroid hormone (PTH), and fibroblast growth factor-23 (FGF-23). OBJECTIVE: This study examined changes in plasma and effluent levels of total calcium, phosphate, PTH, and FGF-23 in individuals undergoing TPE. METHODS: Measurements were taken immediately before, immediately after, and at follow-up. Paired t tests compared the percentage changes in metabolites from pre- to post-TPE. RESULTS: Study participants (N = 42) had a mean age of 55 ± 16 years, 28 (67%) were female, and 32 (76%) were White. TPE led to acute changes in calcium (-9%; 95% CI, -11% to -8%), phosphate (-14%; -18% to -11%), and FGF-23 (-12%; -18% to -6%) concentrations. In contrast, PTH levels increased (91%; 63%-119%) from baseline to post-TPE. While most metabolites returned to baseline by the follow-up visit (median 4 [interquartile range, 3-7] days), nearly 25% of patients experienced persistent asymptomatic hypocalcemia. This persistent calcium deficit was not fully corrected by continuous intravenous calcium gluconate infusions administered during the study, nor by the endogenously increased PTH levels. CONCLUSION: These findings underscore the need for improved care protocols and vigilant monitoring of mineral metabolism in TPE patients, especially those receiving long-term treatment. Further research is warranted to understand the enduring effects of TPE on mineral metabolism and develop strategies to prevent complications.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Jin SS, Dugar A, Hoofnagle AN, et al. Therapeutic Plasma Exchange and Changes in Calcium, Phosphate, Parathyroid Hormone, and Fibroblast Growth Factor-23. J Clin Endocrinol Metab. 2026. PMID: 40663633. doi:10.1210/clinem/dgaf400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。